Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for BYL719

2 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Treatment

VICCBRE12101

04/04/2013

A Phase Ib Trial of BYL719 (an a-Specific PI3K Inhibitor) in Combination with Endocrine Therapy in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer